--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational ...

Arrowhead (ARWR) Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference RNAi therapeutic being ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

It appears that Arrowhead is the first company to start clinical studies against the INHBE target may currently be the only company able to address the ALK 7 target, which utilizes a new version ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

Arrowhead is currently funded into 2028 with ... Initiated a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNAi therapeutic being developed as a potential treatment ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR )周四宣布，即日起任命Douglas Ingram为董事。该公司目前市值26亿美元，过去一年回报率为-35%。 根据InvestingPro分析，尽管近期市场面临挑战，但该公司仍保持强劲的流动性。根据2024年11月25日与Sarepta Therapeutics, ...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...